Market Overview

UPDATE: McNicoll Lewis Vlak Initiates Galena Biopharma at Buy on Cancer Vaccine Potential

Related GALE
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of
UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

McNicoll Lewis Vlak initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $6 price target.

McNicoll Lewis Vlak commented, "As we near the end of Breast Cancer Awareness month, we are initiating coverage on Galena Biopharma Inc. with a BUY recommendation and one-year price target of $6.00 based on the company's lead Phase III asset, a cancer vaccine called NeuVax. An ongoing Phase III trial, being conducted under a Special Protocol Assessment (SPA), is targeting breast cancer patients who are classified as HER2/neu negative but have node-positive disease. Breast cancer affects one in eight women, and we believe NeuVax will be able to prolong the lives of those who are fortunate enough to catch their disease early."

Galena Biopharma closed at $1.88 on Wednesday.

Latest Ratings for GALE

DateFirmActionFromTo
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: mcnicoll lewis vlakAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Get Benzinga's Newsletters